3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other solid neoplasm
1
Conditions
Multiple Myeloma
1
Interventions
Dexamethasone
130
Lenalidomide
82
daratumumab
60
Bortezomib
56
carfilzomib
45
Calcium Dobesilate
41
pomalidomide
37
Cyclophosphamide
31
isatuximab
26
belantamab mafodotin
23
Specimen Handling
21
Biopsy
21
Magnetic Resonance Spectroscopy
18
dexamethasone acetate
16
dexamethasone 21-phosphate
16
ixazomib
15
auricularum
15
fludarabine
13
Melphalan
13
iberdomide
11
elotuzumab
11
selinexor
10
fludarabine phosphate
9
X-Rays
8
talquetamab
7
venetoclax
6
trametinib
6
nirogacestat
6
Whole-Body Irradiation
6
Thalidomide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Antibodies, Monoclonal
×
Plasma cell
×
Clear all
NCT03942224
2024-06-21
DeRIVE
Emory University
Phase 2
Active not recruiting
49 enrolled